Targeting Inhibitor of Apoptosis Proteins to Overcome Chemotherapy Resistance-A Marriage between Targeted Therapy and Cytotoxic Chemotherapy.
Tiago BarrosoCecília Melo-AlvimLeonor Abreu RibeiroSandra CasimiroLuis CostaPublished in: International journal of molecular sciences (2023)
Precision oncology is the ultimate goal of cancer treatment, i.e., to treat cancer and only cancer, leaving all the remaining cells and tissues as intact as possible. Classical chemotherapy and radiotherapy, however, are still effective in many patients with cancer by effectively inducing apoptosis of cancer cells. Cancer cells might resist apoptosis via the anti-apoptotic effects of the inhibitor of apoptosis proteins. Recently, the inhibitors of those proteins have been developed with the goal of enhancing the cytotoxic effects of chemotherapy and radiotherapy, and one of them, xevinapant, has already demonstrated effectiveness in a phase II clinical trial. This class of drugs represents an example of synergism between classical cytotoxic chemo- and radiotherapy and new targeted therapy.
Keyphrases
- locally advanced
- cell cycle arrest
- cell death
- clinical trial
- endoplasmic reticulum stress
- phase ii
- rectal cancer
- oxidative stress
- induced apoptosis
- squamous cell carcinoma
- radiation therapy
- early stage
- pi k akt
- papillary thyroid
- open label
- randomized controlled trial
- radiation induced
- systematic review
- palliative care
- gene expression
- signaling pathway
- photodynamic therapy
- young adults
- drug delivery
- study protocol